Video Experimental Relacionado
Updated: Jul 4, 2025
07:44
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.5K
SMARCAL1 es un regulador dual de la señalización inmune innata y la expresión de PD-L1 que promueve la evasión inmune
Giuseppe Leuzzi1, Alessandro Vasciaveo2, Angelo Taglialatela1
1Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Cell
|February 1, 2024
Resumen
SMARCAL1 promueve la evasión inmune del cáncer suprimiendo la inmunidad innata y aumentando la expresión de PD-L1. Su pérdida aumenta las respuestas antitumorales y la sensibilidad al bloqueo del punto de control inmune, revelando a SMARCAL1 como un objetivo potencial de inmunoterapia.
Área de la Ciencia:
- Biología del cáncer e inmunología
- Mecanismos moleculares de evasión inmune
Sus antecedentes:
- La inestabilidad genómica puede iniciar respuestas inmunes antitumorales.
- Las células cancerosas con frecuencia evaden la vigilancia inmune a través de puntos de control inmunológicos como el PD-L1.
- Comprender los reguladores de la evasión inmune es crucial para una inmunoterapia eficaz contra el cáncer.
Objetivo del estudio:
- Identificar nuevos factores que contribuyen a la evasión inmune del cáncer.
- Aclarar el doble papel de SMARCAL1 en la supresión de la inmunidad innata y la promoción de la expresión de PD-L1.
- Evaluar SMARCAL1 como objetivo terapéutico para mejorar la inmunidad antitumoral.
Principales métodos:
- Investigó la función de la translocación del ADN SMARCAL1 de la familia SNF2 en las células cancerosas.
- Se evaluó el impacto de SMARCAL1 en las vías de señalización inmune innata cGAS-STING.
- Se analizó el papel de SMARCAL1 en la regulación de la expresión de PD-L1 a través de la accesibilidad de la cromatina y la cooperación JUN.
- Se utilizó un modelo de melanoma de ratón para estudiar los efectos de la pérdida de SMARCAL1 en la inmunidad tumoral y la respuesta al bloqueo del punto de control.
Principales resultados:
- SMARCAL1 suprime la señalización inmune innata al limitar el daño endógeno del ADN, inhibiendo así la activación de cGAS-STING.
- SMARCAL1 coopera con JUN para mantener la accesibilidad de la cromatina en el locus PD-L1, promoviendo la expresión de PD-L1.
- La pérdida de SMARCAL1 altera la inducción de PD-L1 bajo estrés genómico, mejora las respuestas inmunitarias antitumorales y mejora la sensibilidad al bloqueo del punto de control inmune in vivo.
Conclusiones:
- SMARCAL1 actúa como un mediador clave de la evasión inmune del tumor a través de un mecanismo dual.
- Dirigirse a SMARCAL1 podría superar la resistencia inmune en el cáncer.
- La inhibición de SMARCAL1 representa una estrategia prometedora para potenciar la inmunoterapia contra el cáncer.
Videos de Conceptos Relacionados
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:31The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K